10. Imaging (CT of neck and chest/ MRI, if indicated, for oropharyngeal cancer participants; CT of skull, neck and chest/ MRI, if indicated, for sinonasal SCC; no CT chest required if PET/CT available) at baseline/screening, and at Week 4-5 (CT of neck/ MRI, if indicated, for oropharyngeal cancer participants; CT of skull, neck/ MRI, if indicated, for sinonasal SCC). MRI (with gadolinium) will be used when CT scan is not an option to follow the disease. Bone scans and other imaging assessments may also be performed as clinically indicated. Post-treatment imaging is to be strongly pursued but is not required and may be waived at the discretion of the PI. 11. Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ENT under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy. For patients that have surgery as definitive treatment, Week 4-5 biopsy may be omitted: in this case tumor biospecimens will be obtained from the institution where the patient underwent surgery after the patient signs that institution’s release document. 12. Where feasible, research blood (see Section 5.1) will be collected at baseline, week 3 and week 45 with the following exceptions: Samples for AVA analysis will be taken prior to infusion on W1, W3, with research labs on 4-5 or with end of treatment labs if participants come off treatment prior to any of those timepoints. Note: Samples may be sent to Precigen, Inc for additional analyses (see Section 5.1.9).